Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Pufang, Li, Xiaogang, Shen, Jun, Feng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530266/
https://www.ncbi.nlm.nih.gov/pubmed/33041818
http://dx.doi.org/10.3389/fphar.2020.574533
_version_ 1783589536194887680
author Tan, Pufang
Li, Xiaogang
Shen, Jun
Feng, Qi
author_facet Tan, Pufang
Li, Xiaogang
Shen, Jun
Feng, Qi
author_sort Tan, Pufang
collection PubMed
description Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.
format Online
Article
Text
id pubmed-7530266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75302662020-10-09 Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update Tan, Pufang Li, Xiaogang Shen, Jun Feng, Qi Front Pharmacol Pharmacology Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients. Frontiers Media S.A. 2020-09-18 /pmc/articles/PMC7530266/ /pubmed/33041818 http://dx.doi.org/10.3389/fphar.2020.574533 Text en Copyright © 2020 Tan, Li, Shen and Feng http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tan, Pufang
Li, Xiaogang
Shen, Jun
Feng, Qi
Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title_full Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title_fullStr Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title_full_unstemmed Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title_short Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update
title_sort fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530266/
https://www.ncbi.nlm.nih.gov/pubmed/33041818
http://dx.doi.org/10.3389/fphar.2020.574533
work_keys_str_mv AT tanpufang fecalmicrobiotatransplantationforthetreatmentofinflammatoryboweldiseaseanupdate
AT lixiaogang fecalmicrobiotatransplantationforthetreatmentofinflammatoryboweldiseaseanupdate
AT shenjun fecalmicrobiotatransplantationforthetreatmentofinflammatoryboweldiseaseanupdate
AT fengqi fecalmicrobiotatransplantationforthetreatmentofinflammatoryboweldiseaseanupdate

Ejemplares similares